A5067044422- Respiratory Support and Mechanisms
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Research Studies
- COVID-19 Clinical Research Studies
- Neuroendocrine Tumor Research Advances
- Mechanical Circulatory Support Devices
- Intensive Care Unit Cognitive Disorders
- Acute Lymphoblastic Leukemia research
- Ultrasound in Clinical Applications
- Neuroblastoma Research and Treatments
- Pneumothorax, Barotrauma, Emphysema
- Antifungal resistance and susceptibility
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Thermal Regulation in Medicine
- Fibroblast Growth Factor Research
- Extracellular vesicles in disease
- Sepsis Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Long-Term Effects of COVID-19
- Abdominal Surgery and Complications
- Pulmonary Hypertension Research and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Hemodynamic Monitoring and Therapy
- Phagocytosis and Immune Regulation
Amsterdam UMC Location Vrije Universiteit Amsterdam
2024-2025
Amsterdam University Medical Centers
2021-2023
Vrije Universiteit Amsterdam
2021-2023
Amsterdam Neuroscience
2023
The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental early clinical data suggest that the tyrosine-kinase inhibitor imatinib reverses pulmonary leak. This randomised, double-blind, placebo-controlled, trial was done at 13 academic non-academic teaching hospitals in Netherlands. Hospitalised patients (aged ≥18 years) with COVID-19, as confirmed by an RT-PCR test for SARS-CoV-2, requiring supplemental oxygen to maintain a...
Background Imatinib reduced 90-day mortality in hospitalised coronavirus disease 2019 (COVID-19) patients a recent clinical trial, but the biological effects that cause improved outcomes are unknown. We aimed to determine changes elicited by imatinib with COVID-19 and what baseline profile moderates effect of imatinib. Methods undertook secondary analysis randomised, double-blind, placebo-controlled trial oral hospitalised, hypoxaemic patients. Mediating plasma concentration 25 host response...
Abstract Purpose A hallmark of acute respiratory distress syndrome (ARDS) is hypoxaemic failure due to pulmonary vascular hyperpermeability. The tyrosine kinase inhibitor imatinib reversed capillary leak in preclinical studies and improved clinical outcomes hospitalized COVID-19 patients. We investigated the effect intravenous (IV) on edema ARDS. Methods This was a multicenter, randomized, double-blind, placebo-controlled trial. Invasively ventilated patients with moderate-to-severe ARDS...
Neurological monitoring in sedated Intensive Care Unit patients is constrained by the lack of reliable blood-based biomarkers. Neurofilament light a cross-disease biomarker for neuronal damage with potential clinical applicability patients. We studied trajectory neurofilament over month diagnosed severe COVID-19 and explored its relation to outcomes pathophysiological predictors. Data were collected 31 (166 plasma samples) at Amsterdam University Medical Centre, first week after emergency...
The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is severe, life-threatening medical condition characterized by widespread inflammation and vascular leak lungs. Although there no proven therapy reduce pulmonary ARDS, recent studies demonstrated that tyrosine kinase inhibitor imatinib reinforces endothelial barrier prevents inflammatory conditions, while...
In the randomized double-blind placebo-controlled CounterCOVID study, oral imatinib treatment conferred a positive clinical outcome and signal for reduced mortality in COVID-19 patients. High concentrations of alpha-1 acid glycoprotein (AAG) were observed these patients associated with increased total concentrations.This post-hoc study aimed to compare difference exposure following administration cancer assess assocations between pharmacokinetic (PK) parameters pharmacodynamic (PD) outcomes...
Lung ultrasound (LUS) can detect pulmonary edema and it is under consideration to be added updated acute respiratory distress syndrome (ARDS) criteria. However, remains uncertain whether different LUS scores used quantify in patient with ARDS.This study examined the diagnostic accuracy of four extravascular lung water index (EVLWi) assessed by transpulmonary thermodilution patients moderate-to-severe COVID-19 ARDS.In this predefined secondary analysis a multicenter randomized-controlled...
Abstract: Although previous studies support the clinical benefit of imatinib regarding respiratory status in hospitalized patients with COVID-19, potential cardiotoxicity may limit its application. This study aimed to investigate cardiac safety COVID-19. In CounterCOVID study, 385 hypoxemic COVID-19 were randomly assigned receive 10 days oral or placebo a 1:1 ratio. Patients corrected QT interval (QTc) >500 ms left ventricular ejection fraction <40% excluded. Severe adverse events...
Abstract Mucormycosis is a severe complication in critically ill COVID-19 patients. Throughout the pandemic, notable prevalence of mucormycosis has been observed Indian population, whereas lower occurrences have reported Europe. However, limited data exist regarding its Europe, which potentially underestimated due to low sensitivity bronchoalveolar lavage (BAL) cultures. We aimed evaluate high-risk population Netherlands, and potential benefit adding Mucor PCR BAL as part routine follow-up....
Background Clinical monitoring of pulmonary edema due to vascular hyperpermeability in ARDS poses significant clinical challenges. Presently, no biological or radiological markers are available for quantifying edema. Our aim was phenotype and permeability patients with COVID-19 ARDS. Methods Transpulmonary thermodilution measurements were conducted 65 on the day intubation determine extravascular lung water index (EVLWi) (PVPi). In parallel, ventilatory parameters, outcomes, volume opacity...
Abstract Background : Lung ultrasound (LUS) is a non-invasive method to detect and quantify pulmonary edema. However, it remains uncertain how components of the LUS examination should be aggregated into score for quantifying We examined diagnostic accuracy various scores with extravascular lung water index (EVLWi) assessed PiCCO in patients moderate-to-severe COVID-19 ARDS. Methods In this predefined secondary analysis multicenter randomized-controlled trial (InventCOVID), were included...
<b>Background:</b> COVID-19 can lead to ARDS, a severe complication requiring invasive ventilation in the ICU. ARDS is characterized by protein-rich pulmonary oedema due alveolar-capillary barrier9s hyperpermeability. <b>Aims:</b> This study aims phenotype patients with variable amounts of using both biological and clinical markers. <b>Methods:</b> Transpulmonary thermodilution was used measure extravascular lung water (EVLW) 65 ARDS. Patients were divided into tertiles based on amount EVLW...
<b>Background:</b> A high incidence of invasive mucormycosis (IM) among COVID-19 patients has been reported, especially in India. In other countries, the prevalence IM critically ill remains unclear. As diagnostic utility respiratory cultures could be low, may die due to undiagnosed IM. <b>Aims and objectives:</b> The aim was determine frequency invasively ventilated Covid-19 patients, who died mono-organ failure. <b>Methods:</b> Retrospectively, deceased ICU from AmsterdamUMC with at least...
<b>Introduction:</b> COVID-19 is often complicated by hypoxemic respiratory failure, resulting from widespread capillary leak. The kinase inhibitor imatinib may protect the endothelial barrier and reverse pulmonary <b>Methods:</b> This was a randomized, double-blind, placebo-controlled trial. Hospitalized patients requiring supplemental oxygen were randomized to oral (800mg loading dose, followed 400mg daily for 9 days) or placebo on top of standard care. primary outcome was time...